数字干预信息对美国心血管疾病成人流感疫苗接种率的影响:卡塔尔世界杯8强波胆分析分散随机对照试验%A Marshall,Nell J %A Lee,Jennifer L %A Schroeder,Jessica %A Lee,Wei-Nchih %A See,Jermyn %A Madjid,Mohammad %A munagid,Mrudula R %A Piette,John D %A Tan,Litjen %A Vardeny,Orly %A Greenberg,Michael %A Liska,Jan %A Mercer,Monica %A Samson,Sandrine %+ Evidation Health, Inc, 63 Bovet Rd #146，美国CA, 94402, 1 (415) 515 1985，nmarshall@evidation.com %K流感%K随机试验%K公共卫生%K心血管疾病%K免疫%K疫苗接种%K数字信息%K数字干预%K移动健康%K移动健康%D 2022 %7 7.10.2022 %9原始论文%J J医学互联网Res %G英语%X背景:季节性流感每年影响5%至15%的美国人，导致可预防的死亡和重大的经济影响。流感感染对心血管疾病患者尤其危险，因此他们是疫苗接种运动的优先群体。目的:我们旨在评估数字干预信息对季节性流感疫苗自我报告率的影响。方法:这是一项随机、对照、单盲和分散的试验，于2020-2021年流感季节在美国各地的个别地点进行。成就移动平台的成员中有自我报告心血管疾病的成年人被随机分配接受或不接受一系列6个以患者为中心的数字干预信息，促进流感疫苗接种。主要终点是随机分组后6个月自报接种率的组间差异。次要结果包括对信息的参与程度以及疫苗接种率和对信息的参与之间的关系。亚组分析检查了不同种族干预效果的差异。 Controlling for randomization group, we examined the impact of other predictors of vaccination status, including cardiovascular condition type, vaccine drivers or barriers, and vaccine knowledge. Results: Of the 49,138 randomized participants, responses on the primary end point were available for 11,237 (22.87%; 5575 in the intervention group and 5662 in the control group) participants. The vaccination rate was significantly higher in the intervention group (3418/5575, 61.31%) than the control group (3355/5662, 59.25%; relative risk 1.03, 95% CI 1.004-1.066; P=.03). Participants who were older, more educated, and White or Asian were more likely to report being vaccinated. The intervention was effective among White participants (P=.004) but not among people of color (P=.42). The vaccination rate was 13 percentage points higher among participants who completed all 6 intervention messages versus none, and at least 2 completed messages appeared to be needed for effectiveness. Participants who reported a diagnosis of COVID-19 were more likely to be vaccinated for influenza regardless of treatment assignment. Conclusions: This personalized, evidence-based digital intervention was effective in increasing vaccination rates in this population of high-risk people with cardiovascular disease. Trial Registration: ClinicalTrials.gov NCT04584645; https://clinicaltrials.gov/ct2/show/NCT04584645 %M 36206046 %R 10.2196/38710 %U //www.mybigtv.com/2022/10/e38710 %U https://doi.org/10.2196/38710 %U http://www.ncbi.nlm.nih.gov/pubmed/36206046